Pharmaceutical companies are adopting direct-to-consumer drug sales, bypassing insurers and PBMs. This strategy impacts drug pricing, patient out-of-pocket costs, and insurance market dynamics in the U.S.
Increasing specialty drug costs lead to greater use of alternative funding programs in employer health plans, raising access and cost concerns amid rising drug prices.
Study reveals limited insurance coverage for multiple sclerosis drugs increases relapse risk, highlighting Medicare plan disparities and formulary restrictions.
Applied Policy names Brittany La Couture as VP of Health Policy, leveraging her Medicare Advantage and CMS expertise to enhance pharmaceutical reimbursement strategies.
Explore major U.S. health policy changes in 2025 affecting insurance access, Medicaid funding, vaccine advisory shifts, and regulatory reforms.
Amazon Pharmacy has expanded PillPack to Medicare, allowing seniors to use pre-sorted medication packets with insurance coverage, enhancing medication management and caregiver support.
Analysis of US insurance data shows no link between return-to-school policies and antibiotic use for conjunctivitis, details on measles cases, COVID-19 impacts on fertility, and benefits of Paxlovid for stroke risk reduction.
April 2025 market update reveals insurer stock declines amid UnitedHealth earnings miss, offset by pharma gains led by Eli Lilly's drug innovation and strong healthcare sector earnings projections.
April 2025 update on U.S. pharmaceutical regulation highlights executive orders, budget changes, CMS policies, IRA litigation, and 340B program developments shaping drug pricing and access.
Dr. Elliott discusses the impact of tariffs on prescription drug prices and answers listener questions on healthcare.
